Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned an average rating of “Buy” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $106.20.

MNPR has been the topic of a number of recent analyst reports. Barclays set a $125.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research note on Monday, October 13th. Raymond James Financial cut shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the company from $142.00 to $123.00 in a research report on Friday, November 14th. BTIG Research upped their target price on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a “buy” rating in a research note on Monday, September 29th. Finally, Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Quan Anh Vu acquired 1,500 shares of the business’s stock in a transaction dated Friday, December 26th. The stock was bought at an average price of $69.95 per share, with a total value of $104,925.00. Following the purchase, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently added to or reduced their stakes in MNPR. Wellington Management Group LLP purchased a new position in shares of Monopar Therapeutics in the third quarter worth about $18,904,000. Deerfield Management Company L.P. bought a new position in Monopar Therapeutics during the 3rd quarter worth approximately $13,048,000. TCG Crossover Management LLC purchased a new position in Monopar Therapeutics in the 3rd quarter worth approximately $12,496,000. Vanguard Group Inc. increased its stake in Monopar Therapeutics by 140.7% in the 3rd quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after purchasing an additional 121,729 shares during the period. Finally, Vivo Capital LLC bought a new stake in Monopar Therapeutics in the third quarter valued at approximately $7,391,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Trading Down 2.5%

Shares of NASDAQ:MNPR opened at $63.40 on Friday. The company has a 50 day moving average of $76.48 and a 200 day moving average of $61.81. The stock has a market cap of $423.51 million, a P/E ratio of -18.43 and a beta of 1.46. Monopar Therapeutics has a 12 month low of $24.00 and a 12 month high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.02). On average, equities analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.